WordNet

the property of eliciting an immune response
possessing the ability to elicit an immune response

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2017/10/15 18:42:41」(JST)

wiki en

Immunogenicity is the ability of a particular substance, such as an antigen or epitope, to provoke an immune response in the body of a human or animal. In other words, immunogenicity is the ability to induce a humoral and/or cell-mediated immune responses.
Differentiation has to be made between wanted and unwanted immunogenicity.

Wanted immunogenicity is typically related with vaccines, where the injection of an antigen (the vaccine) provokes an immune response against the pathogen (virus, bacteria...) aiming at protecting the organism. Vaccine development is a complex multistep process, immunogenicity being at the center of the vaccine efficiency.^[1]
Unwanted immunogenicity is an immune response by an organism against a therapeutic antigen (ex. recombinant protein, or monoclonal antibody). This reaction leads to production of anti-drug-antibodies (ADAs) inactivating the therapeutic effects of the treatment and, in rare cases, inducing adverse effects.^[2] The prediction of the immunogenic potential of novel protein therapeutics is thus a challenge in biotherapy.^[3]

Antigenic immunogenic potency

Proteins are significantly more immunogenic than polysaccharides. T cell response is required to drive immunogenicity.

Since lipids and nucleic acids are non-immunogenic haptens, they require conjugation with an epitope such as a protein or polysaccharide before they can evoke an immunologic response.

Proteins or polysaccharides are used for studies of humoral immune response.
Only proteins can serve as immunogens for cell-mediated immunity.

Protein drugs

In the rush to deliver novel biologics to market, developers have, on occasion, overlooked factors that contribute to protein immunogenicity. In addition, autologous or human-like proteins have proven to be surprisingly immunogenic in some applications, suggesting that assumptions about immune tolerance, too, require careful consideration in biologics design.

Fortunately, years of thorough study of the parameters influencing vaccine efficacy allow parallels to be drawn for protein therapeutics. Factors including delivery route, delivery vehicle, dose regimen, aggregation, innate immune system activation, and the ability of the protein to interface with the humoral (B cell) and cellular (T cell) immune systems, all impact the potential immunogenicity of vaccine immunogens when delivered to humans (for reviews related to unwanted immunogenicity determinants, see references below).

Like vaccines, protein therapeutics can engender both cellular and humoral immune responses. Anti-drug antibodies (ADA) may neutralize the therapeutic effects of the drug and/or alter its pharmacokinetics. B cells are certainly involved in this immune response when IgG class ADA are observed, because antibody isotype switching is a hallmark of B-dependent antigens.

More serious adverse events can be provoked if ADA cross-react with a critical autologous protein. Examples of adverse ADA responses include autoimmune thrombocytopenia (ITP) following exposure to recombinant thrombopoietin, and pure red cell aplasia, which was associated with a particular formulation of erythropoietin (Eprex). Since the impact of immunogenicity can be quite severe, regulatory agencies are developing risk-based guidelines for immunogenicity screening.

Antigens

Immunogenicity is influenced by multiple characteristics of an antigen:

Phylogenetic distance
Molecular size
Epitope density
Chemical composition and heterogeneity

Protein structure, aa-polymers, Glu-Lys, Tyr, Phe

Degradability (ability to be processed & presented to T cells)

D-amino acids

Evaluation methods

In silico screening. T cell epitope content, which is one of the factors that contributes to the risk of immunogenicity can now be measured relatively accurately using in silico tools. Immunoinformatics algorithms for identifying T-cell epitopes are now being applied to triage protein therapeutics into higher risk and low risk categories.

One approach is to parse protein sequences into overlapping 9-mer peptide frames, each of which is then evaluated for binding potential to each of eight common class II HLA alleles that “cover” the genetic backgrounds of most humans worldwide. By calculating the density of high-scoring frames within a protein, it is possible to estimate a protein’s overall “immunogenicity score”. In addition, sub-regions of densely packed high scoring frames or “clusters” of potential immunogenicity can be identified, and cluster scores can be calculated and compiled. Given the resulting “immunogenicity score” of a protein, and taking into consideration other determinants of immunogenicity as described above, it is possible to make an informed decision about the likelihood that a protein will provoke an immune response.

Using this approach, the clinical immunogenicity of a novel protein therapeutics can be calculated and consequently a number of biotech companies have integrated in silico immunogenicity into their pre-clinical process as they develop new protein drugs.

T cell epitopes

De-immunization by epitope modification is a strategy for reducing immunogenicity based on disruption of HLA binding, an underlying requirement for T cell stimulation. The idea of rational epitope modification is rooted in the natural process that occurs when tumor cells and pathogens evolve to escape immune pressure by accumulating mutations that reduce the binding of their constituent epitopes to host HLA, rendering the host cell unable to “signal” to T cells the presence of the tumor or pathogen. Deimmunized protein therapeutics are now entering the clinic; initial results appear to support this approach to reducing immunogenicity risk. Several methods exist for deimmunization by epitope modification for reduced immunologic potential in-vitro, in-vivo and ex-vivo.^[4]

References

^ Leroux-Roels G. "Vaccine development". Perspectives in Vaccinology. 1: 115–150. doi:10.1016/j.pervac.2011.05.005.
^ De Groot A.S.; Scott D.W. "Immunogenicity of protein therapeutics". Trends in Immunology. 28: 482–490. doi:10.1016/j.it.2007.07.011.
^ Baker M.P.; et al. (10 2010). "Immunogenicity of protein therapeutics". Self Nonself. 1: 314–322. PMC 3062386 . PMID 21487506. doi:10.4161/self.1.4.13904. Check date values in: |date= (help)
^ Jawa, Vibha; AS Degroot; L Cousens; M Awwad; H. Kropshofer; E. Wakshull (December 2013). "T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation". Clinical Immunology. 149 (3): 534–555. doi:10.1016/j.clim.2013.09.006.

Immunologists' Toolbox: Immunization. In: Charles Janeway, Paul Travers, Mark Walport, Mark Shlomchik: Immunobiology. The Immune System in Health and Disease. 6th Edition. Garland Science, New York 2004, ISBN 0-8153-4101-6, p. 683–684
Descotes Jacques (Mar 2009). "Immunotoxicity of monoclonal antibodies". MAbs. 1 (2): 104–111. PMC 2725414 . PMID 20061816. doi:10.4161/mabs.1.2.7909.
The European Immunogenicity Platform http://www.e-i-p.eu
De Groot AS, Martin W (2009). "Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics". Clin Immunol. 131 (2): 189–201. doi:10.1016/j.clim.2009.01.009.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 慢性肝疾患患者のための予防接種 immunizations for patients with chronic liver disease
2. HIV感染成人における肺炎球菌ワクチンの接種 pneumococcal immunization in hiv infected adults
3. HIV感染患者における予防接種 immunizations in hiv infected patients
4. 髄膜炎菌ワクチン meningococcal vaccines
5. ヒトパピローマウイルス（HPV）ワクチンの臨床試験 clinical trials of human papillomavirus vaccines

English Journal

Efficient production of Tymovirus like particles displaying immunodominant epitopes of Japanese Encephalitis Virus envelope protein.

Shahana PV1, Das D2, Gontu A2, Chandran D2, Maithal K3.
Protein expression and purification.Protein Expr Purif.2015 Sep;113:35-43. doi: 10.1016/j.pep.2015.03.017. Epub 2015 May 7.
Japanese Encephalitis (JE) is a mosquito borne arboviral infection caused by Japanese Encephalitis Virus (JEV). It is a major cause of viral encephalitis in Asian countries including India. In the present study, we have used a Tymovirus [i.e. Physalis Mottle Virus (PhMV) coat protein (CP)], which fo
PMID 25959459

Immunological features of T cells induced by human telomerase reverse transcriptase-derived peptides in patients with hepatocellular carcinoma.

Mizukoshi E1, Nakagawa H1, Kitahara M1, Yamashita T1, Arai K1, Sunagozaka H1, Fushimi K1, Kobayashi E2, Kishi H2, Muraguchi A2, Kaneko S3.
Cancer letters.Cancer Lett.2015 Aug 10;364(2):98-105. doi: 10.1016/j.canlet.2015.04.031. Epub 2015 May 14.
Human telomerase reverse transcriptase (hTERT) is a catalytic enzyme required for telomere elongation. In this study, we investigated the safety and immunogenicity of an hTERT-derived peptide (hTERT461) as a vaccine and characterized the hTERT-specific T cell responses induced. Fourteen hepatocellul
PMID 25982205

Immunogenicity and anti-fecundity effect of nanoparticle coated glutathione S-transferase (SjGST) DNA vaccine against murine Schistosoma japonicum infection.

Mbanefo EC1, Kumagai T2, Kodama Y3, Kurosaki T3, Furushima-Shimogawara R2, Cherif MS4, Mizukami S4, Kikuchi M4, Huy NT5, Ohta N2, Sasaki H3, Hirayama K6.
Parasitology international.Parasitol Int.2015 Aug;64(4):24-31. doi: 10.1016/j.parint.2015.01.005. Epub 2015 Jan 17.
There is still urgent need for a vaccine against schistosomiasis, especially in Schistosoma japonicum endemic areas where even a vaccine that will interrupt zoonotic transmission will be potentially effective as an intervention tool. We had developed a novel nanoparticle gene delivery system, which
PMID 25603531

Japanese Journal

Immunogenicity of a Candidate DNA Vaccine Based on the prM/E Genes of a Dengue Type 2 Virus Cosmopolitan Genotype Strain

Japanese Journal of Infectious Diseases 68(5), 357-363, 2015-09
NAID 40020599944

当医科大学学生・附属看護専門学校学生におけるB型肝炎ワクチン接種成績の検討 : ワクチン接種1シリーズ終了後および1年後のHBs抗体価の推移について

Dokkyo journal of medical sciences 42(2), 63-70, 2015-07-25
NAID 110009929976

Crystal structure of streptavidin mutant with low immunogenicity(ENZYMOLOGY, PROTEIN ENGINEERING, AND ENZYME TECHNOLOGY)

Journal of bioscience and bioengineering 119(6), 642-647, 2015-06
NAID 110009970751

Related Pictures

Tim Hickling: Applying in vitro immunogenicity assays to predict clinical Immunogenicity Assessment of Tumor Necrosis Factor Antagonists in the Clinical Factors underlying Immunogenicity As elaborated in the text, the | Download Antigen. - ppt video online download Immunogenicity Overview of Therapeutic Biologics – Creative Biolabs Blog What is the difference between antigenicity and immunogenicity? - Quora A Case For One Assay Analysis Of PK And Immunogenicity In Biosimilar Research